Results 131 to 140 of about 8,704 (178)

Eplerenone

Reactions Weekly, 2023
openaire   +1 more source

Eplerenone in pregnancy

Obstetric Medicine
Eplerenone is a mineralocorticoid receptor antagonist with minimal affinity for androgen receptors. Mineralocorticoid receptor antagonists are efficacious in the management of resistant hypertension, obstructive sleep apnea, cardiac dysfunction, renal tubular disorders, hepatic cirrhosis, portal hypertension, diabetic nephropathy, proteinuric kidney ...
openaire   +2 more sources

Eplerenone

Drugs of the Future, 1999
X. Rabasseda, J. Silvestre, J. Castañer
openaire   +1 more source

Eplerenone (GD Searle & Co).

Current opinion in investigational drugs (London, England : 2000), 2001
Eplerenone, an aldosterone receptor antagonist from Searle is being developed as a potential treatment for renal disease, congestive heart failure and hypertension. It is in phase III clinical trials 1312280], [353548]. Monsanto (now Pharmacia) expects to launch the compound in 2002 [370466]. Pharmacia anticipates filing for congestive heart failure in
Martin, J. H., Krum, H.
openaire   +2 more sources

Eplerenone

Reactions Weekly, 2016
openaire   +2 more sources

Effect of eplerenone on clinical stability of Japanese patients with acute heart failure

International Journal of Cardiology, 2023
Masafumi Kitakaze, João Pedro Ferreira, Masatake Kobayashi   +2 more
exaly  

Eplerenone

Reactions Weekly, 2019
openaire   +1 more source

Amlodipine/eplerenone

Reactions Weekly, 2023
openaire   +1 more source

Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability

Drug Delivery, 2021
Muhammad Ayub Khan, Jin-Ki Kim, Abida Raza   +2 more
exaly  

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms

Circulation, 2012
Bertram Pitt, Faiez Zannad, John Vincent   +2 more
exaly